FY2025 EPS Estimates for Edwards Lifesciences Co. (NYSE:EW) Decreased by Analyst

Edwards Lifesciences Co. (NYSE:EW) – Leerink Partnrs dropped their FY2025 earnings estimates for shares of Edwards Lifesciences in a report released on Wednesday, July 24th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings of $2.50 per share for the year, down from their previous estimate of $3.10. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.71 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2026 earnings at $2.82 EPS, FY2027 earnings at $3.17 EPS and FY2028 earnings at $3.48 EPS.

Several other brokerages have also recently commented on EW. JPMorgan Chase & Co. cut shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $105.00 to $72.00 in a research report on Thursday, July 25th. Wells Fargo & Company dropped their target price on shares of Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating for the company in a research report on Thursday, July 25th. Canaccord Genuity Group dropped their target price on shares of Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Stifel Nicolaus dropped their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Finally, Barclays decreased their price target on shares of Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating on the stock in a report on Friday, July 26th. Fourteen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $82.10.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $63.64 on Monday. The firm has a 50 day moving average of $86.92 and a 200-day moving average of $86.84. The stock has a market capitalization of $38.35 billion, a PE ratio of 27.43, a PEG ratio of 2.33 and a beta of 1.11. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the previous year, the company earned $0.66 EPS. The business’s revenue was up 6.7% on a year-over-year basis.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 857 shares of the company’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $85.60, for a total transaction of $73,359.20. Following the transaction, the vice president now owns 23,890 shares in the company, valued at $2,044,984. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The disclosure for this sale can be found here. Insiders have sold 59,449 shares of company stock valued at $5,168,879 in the last ninety days. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently added to or reduced their stakes in EW. Park Avenue Securities LLC grew its position in Edwards Lifesciences by 0.5% during the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock valued at $2,169,000 after buying an additional 108 shares during the period. Martin Capital Advisors LLP lifted its holdings in Edwards Lifesciences by 0.5% during the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after purchasing an additional 128 shares during the last quarter. City State Bank boosted its position in Edwards Lifesciences by 16.5% during the second quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after purchasing an additional 130 shares during the period. Chapin Davis Inc. increased its stake in shares of Edwards Lifesciences by 1.7% in the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after purchasing an additional 140 shares in the last quarter. Finally, Johnson Financial Group Inc. raised its position in shares of Edwards Lifesciences by 23.0% in the fourth quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 144 shares during the period. 79.46% of the stock is owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.